Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The user has been using Minoxidil, Finasteride, and HRT for hair regrowth, but is not fully satisfied with the progress after 11 months. They are considering changing treatments, including possibly switching to Dutasteride and adjusting their HRT regimen.

A 23-year-old male with early stage 4 hair loss is using a treatment routine that includes minoxidil 5% with tretinoin once daily, finasteride 1mg every other day, 2.5mg oral minoxidil every other day, and derma rolling twice a week. The discussion is about whether using minoxidil twice a day is better than combining it with tretinoin once a day.

Amplifica is developing new molecules for hair growth, with clinical trials expected soon, while Engraft Technologies is improving FUE robotic technology to make hair transplants faster and cheaper. Users express interest in the timeline for AMP-303 and concerns about high costs and effectiveness of current treatments.

A 24-year-old male used a daily oral combination of minoxidil (3mg) and finasteride (1.2mg) for three months, along with weekly microneedling, and reported significant hair regrowth and thickness improvement without side effects. Some users expressed skepticism about the rapid results, while others shared their own experiences and congratulated the progress.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

The user experienced significant hair regrowth after one year on male-to-female hormone replacement therapy (HRT) and nine months using minoxidil and finasteride. They noted a reduction in body hair and attributed much of the hair regrowth to the addition of minoxidil.

A user shared impressive hair regrowth results after 4 months using topical minoxidil, oral finasteride, and 3 PRP sessions. They plan to continue with these treatments and add dermastamping.

The user shared their 4-month progress using oral finasteride and topical minoxidil, with a specific application routine. They adjust the minoxidil application to manage costs, applying it daily with variations in quantity and additional tretinoin on certain days.

A user is using minoxidil, finasteride, and tretinoin for hair regrowth. They are advised to be patient for results and to check for vitamin deficiencies.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.

A user inquired about Cipla Tugain Men, a topical solution containing Minoxidil 5% and Finasteride 0.1%, noting its less greasy texture and good price. Responses suggest it's similar to other products with the same ingredients, questioning the effectiveness of additional components.

The conversation humorously discusses hair regrowth treatments, specifically minoxidil and finasteride, with a user claiming significant hair loss reduction using oral minoxidil. It highlights varying responses to treatments and the frustration of hair loss.

PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.

The user has been using Minoxidil and Finasteride for hair loss since December 2025, experiencing slower progress compared to others, and is considering additional treatments like Exosomes. Other users share similar experiences with delayed results and suggest patience, while some recommend exploring other treatments or consulting a doctor for underlying causes.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to maintain hair production and potentially increasing transplant yield. The conversation questions if this method is practiced in clinics or remains theoretical, and whether it relates to hair cloning or multiplication.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The user shared progress pictures showing hair improvement from using oral finasteride and topical minoxidil between September 2023 and May 2026. Responses express amazement at the results.

A user shared their hair regrowth progress using a regimen of finasteride, minoxidil, derma stamping, red light therapy, and supplements like biotin and vitamin D. They also use keto shampoo and Alpecin C1 shampoo, exercise regularly, and follow a keto diet.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

The user shared their positive experience with hair transplants in Turkey, detailing two sessions with a total of 10,100 grafts. They also use minoxidil, finasteride, and vitamin supplements like biotin and zinc for maintenance.

A 28-year-old male experienced hair regrowth using a topical spray containing minoxidil, finasteride, and tretinoin, along with occasional microneedling, after stopping oral finasteride due to side effects. He is pleased with the progress after three months and plans to continue using the spray.

The user has been using a topical combination of finasteride, minoxidil, and dermastamping for three months to address hair loss. They are considering adding tretinoin and are discussing the effectiveness of topical versus oral treatments.

The conversation is about choosing the right concentration of tretinoin cream to enhance the absorption of minoxidil for hair loss treatment. The options discussed are 0.5, 0.05, 0.25, and 1mg/g concentrations.

User is impressed with 3-month progress using Hims oral finasteride, minoxidil, and biotin. Encouragement to view hair loss treatment as a long-term strategy.

The user has been using finasteride for two years without results and recently started a new routine involving derma stamping, retinol, and minoxidil, which seems to show progress. The user microneedles about half the week and uses L’Oréal night serum for retinol.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.